Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.42), $0.04 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $504 thousand versus the consensus estimate of $480 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook